Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Rigrodsky & Long, P.A. Announces Investigation Of Onyx Pharmaceuticals, Inc. Buyout

Rigrodsky & Long, P.A.:

  • Do you own shares of Onyx Pharmaceuticals, Inc. (NASDAQ GS: ONXX)?
  • Did you purchase any of your shares prior to August 25, 2013?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Onyx Pharmaceuticals, Inc. (“Onyx” or the “Company”) (NASDAQ GS: ONXX) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Amgen Inc. (“Amgen”) (NASDAQ GS: AMGN) in a transaction valued at approximately $10.4 billion.

Click here to learn more: http://www.rigrodskylong.com/investigations/onyx-pharmaceuticals-inc-onxx.

Under the terms of the agreement, public shareholders of Onyx will receive $125.00 per share in cash for each share of Onyx they own.

The investigation concerns whether Onyx’s board of directors failed to adequately shop the Company and obtain the best possible value for Onyx’s shareholders before entering into an agreement with Amgen. According to Yahoo! Finance, at least one analyst has set a price target for Onyx stock at $160.00 per share.

If you own the common stock of Onyx and purchased your shares before August 25, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brian Long or Shaye Fuchs at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/onyx-pharmaceuticals-inc-onxx.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today